Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-07-12

Clinical Trial Update: Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) [Phase 2]

View source ↗

Summary

Phase 2 trial update for preoperative gefitinib in EGFR-mutant II-IIIa non-small cell lung cancer (ECTOP-1001) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gefitinib (Gefitinib)

Snippet

Sponsor: Fudan University | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: COMPLETED